NexCourse is our approach for solid tumor testing.

NexCourse tests can indicate whether or not a patient:

• Is likely to respond to certain treatments
• May be at risk for increased toxicity from certain treatments

NexCourse helps physicians make more informed clinical decisions.

Why NexCourse?

Molecular testing helps to predict patient response.

The stage of cancer broadly helps to determine treatment options. Yet, individual patient differences exist, which may affect how each patient will respond. This is where molecular testing can help.

NexCourse molecular markers can help indicate whether or not a patient is likely to respond to certain treatments, and which treatments may be ineffective or toxic. This can help guide treatment decisions, which may improve patient care.

NexCourse™ is a registered trademark of Genoptix, Inc.